Filing Flows › Comparisons › TNGX vs CYRX
Tango Therapeutics vs Cryoport: TNGX and CYRX compared
Tango Therapeutics is the larger company: $53.8M of revenue in its latest quarter (Q3 2025) against $50.2M for Cryoport (Q3 2026). Tango Therapeutics is growing faster (+364% against +14% a year earlier). Tango Therapeutics is more profitable, with an operating margin of 26.2% against -17.5%.
Where the money goes: TNGX and CYRX
Tango Therapeutics (TNGX) · Q3 2025
Tango Therapeutics, Q3 2025: revenue $53.8M (+364% year over year), operating margin 26.2%, net earnings $15.9M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
Cryoport (CYRX) · Q3 2026
Cryoport, Q3 2026: revenue $50.2M (+14% year over year), operating margin -17.5%, net loss $10.9M, operating cash flow $5.2M. The chart follows the revenue to costs, profit and cash.
| Tango Therapeutics (TNGX) | Cryoport (CYRX) | |
|---|---|---|
| Latest quarter | Q3 2025 | Q3 2026 |
| Revenue | $53.8M | $50.2M |
| Revenue growth, Y/Y | +364% | +14% |
| Operating margin | 26.2% | -17.5% |
| Net earnings | $15.9M | −$10.9M |
| Net margin | 29.5% | -21.6% |
| Operating cash flow | −$31.0M | $5.2M |
Where the revenue comes from
Cryoport
- Service: $28.6M (57%)
- Product: $21.7M (43%)
Questions
Which is bigger, Tango Therapeutics or Cryoport?
Tango Therapeutics is the larger company: $53.8M of revenue in its latest quarter (Q3 2025) against $50.2M for Cryoport (Q3 2026).
Is Tango Therapeutics or Cryoport growing faster?
Tango Therapeutics is growing faster (+364% against +14% a year earlier).
Which is more profitable, Tango Therapeutics or Cryoport?
Tango Therapeutics is more profitable, with an operating margin of 26.2% against -17.5%.
More: Tango Therapeutics earnings · how Tango Therapeutics makes money · Cryoport earnings · how Cryoport makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2025; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.